David Cantor, MD, PhD

Medical Oncology
Accepting new patients
Sees patients age 18 and up
Abramson Cancer Center Perelman 2nd Floor West
Make an appointmentCall 215-615-5858
Headshot of David Cantor, MD, PhD
Penn Medicine Provider

About me

  • Assistant Professor of Clinical Medicine (Hematology-Oncology)

My education and training

  • Medical School: New York University School of Medicine
  • Residency: University of Pennsylvania Health System
  • Fellowship: University of Pennsylvania Health System

Spoken languages

English
English

Insurance accepted

Please contact the practice and/or the member services department of your insurance company for specific details before receiving services. Providers may participate in some, but not all, products offered by a health plan; providers may also accept plans at some practice locations but not others.

Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
Dr. Cantor is a Penn Medicine physician.

Qualifications and experience

Treatments and Conditions

Research

Publications

Cantor DJ, Nimeiri H, Horn L, West M, Ben-Shachar R, Huerga I, Patel JD, Aggarwal C. Outcomes Following First-Line Immune Checkpoint Inhibitors With or Without Chemotherapy Stratified by KRAS Mutational Status-A Real-World Analysis in Patients With Advanced NSCLC. , Clin Lung Cancer.: 2025

Marmarelis ME, Cantor DJ, Mathew D, McWilliams T, Bauml JB, Hwang W, Zhang J, Singh A, D’Avella C, Davis C, Ye D, Sun L, Ciunci C, Zhang N, Aggarwal C, Cohen RB, Minn A, Wherry J, Langer CJ. Phase II Study of Pembrolizumab and Itacitinib for Patients with Treatment Naive Metastatic NSCLC Expressing PD-L1: Long-Term Follow Up. , World Conference on Lung Cancer Annual Meeting, San Diego, CA.: 2024

Cantor DJ, Davis C, Ciunci C, Aggarwal C, Evans T, Alley E, Cohen RB, Bauml JM, and Langer CJ. Long-term followup of adjuvant pembrolizumab following locally ablative therapy for oligometastatic non-small cell lung cancer. , Texas Lung Conference, Austin, TX.: 2024

Cantor DJ, Davis C, Ciunci C, Aggarwal C, Evans T, Cohen RB, Bauml JM, Langer CJ. Brief Report: Long-Term Follow-Up of Adjuvant Pembrolizumab After Locally Ablative Therapy for Oligometastatic NSCLC , JTO Clin Res Rep , 5(6): 2024,100667.

Cantor DJ, Aggarwal C. Targeting KRAS-mutated NSCLC – novel TKIs and beyond. , Clin Cancer Res, 29(18): 2023,3563-3565.

Cantor DJ, Davis C, Ciunci C, Aggarwal C, Evans T, Alley E, Cohen RB, Bauml JM, and Langer CJ. Long-term followup of adjuvant pembrolizumab following locally ablative therapy for oligometastatic non-small cell lung cancer. , American Society of Clinical Oncology Annual Meeting, Chicago, IL.: 2023

Cantor DJ, King B, Blumenberg L, DiMauro T, Aifantis I, Koralov SB, Skok JA, David G. Impaired Expression of Rearranged Immunoglobulin Genes and Premature p53 Activation Block B Cell Development in BMI1 Null Mice , Cell Rep , 26(1): 2019,108-118.e4.

Bainor AJ, Saini S, Calderon A, Polanco RC, Ramirez BG, Monte CM, Cantor DJ, Ernlund A, Litovchick L, David G. The HDAC-associated Sin3B protein represses DREAM complex targets and cooperates with APC/C to promote quiescence. , Cell Rep, 25(10): 2018,2797-2807.e8.

Cantor DJ and David G. The potential of targeting Sin3B and its associated complexes for cancer therapy. , Expert Opin Ther Targets , 21(11): 2017,1051-1061

Bainor AJ, Deng FM, Wang Y, Lee P, Cantor DJ, Logan SK, David G. Chromatin-associated protein Sin3B prevents prostate cancer progression by inducing senescence. , Cancer Res , 77(19): 2017,5339-5348.